WO1995005388A1 - AZIDE DERIVATIVES SUITABLE FOR PREPARATION OF 99mTc COMPLEXES FOR IMAGING AND THEIR USE - Google Patents
AZIDE DERIVATIVES SUITABLE FOR PREPARATION OF 99mTc COMPLEXES FOR IMAGING AND THEIR USE Download PDFInfo
- Publication number
- WO1995005388A1 WO1995005388A1 PCT/US1994/009107 US9409107W WO9505388A1 WO 1995005388 A1 WO1995005388 A1 WO 1995005388A1 US 9409107 W US9409107 W US 9409107W WO 9505388 A1 WO9505388 A1 WO 9505388A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- molecule
- tco
- compound according
- Prior art date
Links
- 0 *c1ccccc1 Chemical compound *c1ccccc1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
- C07F13/005—Compounds without a metal-carbon linkage
Definitions
- the present invention is in the field of isotopic labeling for functional and radiodiagnostic imaging and concerns the preparation of radiolabeled agents for use in such imaging. More specifically, the present invention concerns novel azidoalkyl derivatives of targeting molecules, i.e. molecules having an affinity to a specific target such as a ligand for a receptor, which may be utilized for the preparation of " m Tc labeled agents which serve for radioimaging.
- the present invention further concerns the preparation of these azidoalkyl derivatives, radiolabelled agents prepared therefrom and the preparation of these agents and kits containing said derivatives.
- Imaging is a tool of major importance in medical diagnosis, evaluation of treatment efficacy and in basic medical research.
- functional imaging techniques such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) turned functional brain imaging into a field of increasing importance in the area of medical imaging.
- PET positron emission tomography
- SPECT single photon emission computed tomography
- D 2 -dopamine receptors The in vivo imaging of D 2 -dopamine receptors (to be referred to at times as "D 2 receptors") is very important for basic research, diagnosis and therapy of various neurological and psychiatric disorders such as Parkinson's disease (Scatton et al. 1982; Lee et al. 1980), Huntington's chorea (Reisine et al, 1977), tardive dyskinesia (Goetz et al, 1982) and schizophrenia (Lee et al, 1980).
- Spiperone a neuroleptic molecule which has a high affinity for D 2 receptors has been used for D, receptors imaging mostly by the PET technique.
- spiperone derivatives prepared for use in PET imaging have been labeled with n C (Wagner et al, 1983; Wong et al, 1986), 76 Br (Maziere et al, 1984) and 18 F (Arnett et al, 1987; Arnett et al, 1985; Satyamurthy et al, 1986; Welch et al, 1986) with the 18 F being the most useful due to its relatively longer half-life and its relative ease of production and superior emission characteristics.
- n C Magnetic et al, 1983; Wong et al, 1986
- 76 Br Meziere et al, 1984
- 18 F Alf
- the relative short half-life of these radioisotopes, their high prices and the very high costs involved in the establishment of a PET center greatly reduces the wide ⁇ spread use of D 2 receptors imaging by this technique.
- 125 I labeling has a number of disadvantages which considerably limit its use, for one it is known that iodine-labeled materials are often unstable under physiological conditions; additionally, 125 I has a short half-life; and furthermore the preparation of radioactive iodine is relatively expensive.
- Tc is the most widely used radioisotope in today's nuclear medicine. This is due to the fact that the energy of its ⁇ -irradiation is suitable for medical purposes, it is readily available and it has a low price.
- the approach to 99m Tc complexation has generally been to bind "" c to a known chelate and thereafter modify the chelate to enable its binding to the molecule responsible for localization in the body. This approach invariably causes large changes in the physical and biological characteristics of the 99m Tc labeled molecule.
- the invention is based on a new approach of direct labeling of a targeting molecule with 99m Tc.
- novel compounds useful for the preparation of 99m Tc complexes which may be utilised in radioimaging are provided.
- the complexes prepared according to the present invention do not use bulky chelates to bind the 99m Tc to the targeting molecules and accordingly there are only minimal changes in the structural and binding characteristics of said targeting molecule.
- the present invention thus provides a compound of the formula I:
- T is a targeting group derived from a molecule T which has an affinity to a specific body tissue said targeting group essentially retaining the specific affinity of said molecule;
- R is a branched or straight alkane chain having 1 to 6 carbon atoms; and
- Y is azide (-N 3 ).
- T may be derived from a large number of T molecules each one having an affinity to a specific tissue.
- Such molecules may be ligands of receptors, various agents which have an affinity to certain types of cells or tissue, agents which avoid certain cells or tissue and the like.
- T molecules are the following: (i) Ligands of dopamine receptors such as azidoalkylspiperone derivatives, represented by the following formula II
- groups R a to R. independently represent the group RH, wherein R is as defined for formula I, and m and n are integers which are independently 0-6.
- R in the above Formulae I-V has preferably 1 to 4 carbon atoms, with 2 carbon atoms being the most preferred.
- T is spiperone, which is a ligand of the D 2 receptor and which is represented by the following formula VI
- the present invention also provides a process for preparing a compound of the formula I comprising the steps:
- step (b) reacting the molecule of step (a) with a di-p-tosylate having the general formula VII wherein R is as defined above for formula I;
- step (c) reacting the product of step (b) with a compound capable of donating an azide anion, e.g. amberlite azide.
- the reaction product of step (c) in the above process may suitably be separated from the reaction mixture by chromatography.
- a method for the preparation of a radioisotopic agent useful for in vivo imaging comprising:
- R 5 is independently in each case alkyl, aryl, arylalkyl, heteroaryl, and h ⁇ teroarylalkyl, optionally substituted by a functional group such as SO 3 , CN, OH, SH and NH 3 ;
- X is CH,; and
- n is 1, 2 or 3; can be used as oxygen acceptors in organometallic reactions such as the one described above with TcO 4 " .
- Using such an oxygen acceptor is expected to increase the yield of the final spiperone- 99m Tc complex and accordingly it is preferred in accordance with the invention to add such an an oxygen acceptor to the reaction mixture in step (b) above.
- the solution obtained in method step (c) may be used for imaging as is or alternatively and preferably, the obtained complex is separated from the solution prior to its use. In some specific cases it might be necessary to add a base to neutralise the resulting hydronium salt of said target molecule in the complex prior to its use.
- X is an organic anion of the structure R ⁇ OO " wherein R 1 is hydrogen or a - branched or straight chain alky] optionally substituted ' by halogen atoms, e.g. 1 to 3, or by hydroxyl, e.g. 1 to 3, or an organic anion of the structure R 2 (COOO ⁇ ) 2 wherein R 2 is a -C 6 branched or straight chain alkylene optionally substituted by halogen atoms, e.g. 1 to 3, or hydroxyl, e.g. 1 to 3.
- R 1 is hydrogen or a - branched or straight chain alky] optionally substituted ' by halogen atoms, e.g. 1 to 3, or by hydroxyl, e.g. 1 to 3, or an organic anion of the structure R 2 (COOO ⁇ ) 2 wherein R 2 is a -C 6 branched or straight chain alkylene optionally substituted by halogen atoms, e.g. 1 to
- any acid capable of reducing the technetium from the heptavalent state to the lower valency needed for preparing the complex may be used in accordance with the present invention.
- the acids may be inorganic or organic acid, hydrochloric acid and succinic acid being presently preferred.
- Examples of specific pertechnetates of 99m Tc that can be used in accordance with the above method of the present invention are Na 99m Tc0 4 , NH 4 99m TcO 4 or K" m TcO 4 .
- 99m Tc has a half life time of about 6 hrs it is preferred that the actual preparation of the complex be carried out only shortly before the intended use of the agent.
- the present invention further provides an agent useful for radioimaging being a complexation product of the compounds of formula I and of "" c.
- the invention further provides a kit which may be utilized by a diagnostic laboratory for the preparation of the above complexation product comprising at least one container holding a compound of formula I optionally containing one or more additional containers holding a suitable acid solution.
- Spiperone hydrochloride 500 mg was dissolved by heating in distilled water (105 ml). After cooling IN NaOH (1.23 ml) was added. The solution was filtered and then dried under high vacuum resulting in 376 mg of spiperone (82% yield). The product was identified by TLC, m.p. and microanalysis. The m.p. was found to be 208-210°C (lit m.p. 208.6- 210°C (Janssen Pharmaceutica, 1990)). Micronalysis:
- Azidoethylspiperone (2 mg) was dissolved in saline (1 ml) by heating and stirring for 15 min at 100°C. 2.6 ml 10 N HCl were added while continuing heating during 4 min. 1 ml saline solution of " m TcO " was added and the reaction mixture was heated further during 30 min.
- reaction mixture was separated by one and two dimensional chromatography on silica TLC plates.
- One dimensional TLC was performed in acetonitrile.
- Two dimensional chromatography was performed in MeOH-Benzene-CH 2 Cl 2 - DDW (2:1:1:0.05). The plates were cut into strips and counted.
- the labeled spiperone complex had a yield of 30-50%.
- Rhenium (Re) is a compound of group Vllb of the periodic table of chemical elements, to which group technetium also belongs, and accordingly the chemical properties of these two compounds are very similar.
- the preparation of a complex with Re is thus very similar to the preparation of a complex with " m Tc.
Abstract
A compound which can be complexed with 99mTc, has the formula T-R-Y wherein T is a targeting group derived from a molecule T' which has an affinity to a specific body tissue said targeting group essentially retaining the specific affinity of said molecule; R is a branched or straight alkane chain having 1 to 6 carbon atoms; and Y is azide-N¿3?. The complexion product of ?99m¿Tc and the above compound is useful for in vivo radio-imaging.
Description
AZIDE DERIVATIVES SUITABLE FOR PREPARATION OF 99m Tc COMPLEXES FOR IMAGING AND THEIR USE
FIELD OF THE INVENTION
The present invention is in the field of isotopic labeling for functional and radiodiagnostic imaging and concerns the preparation of radiolabeled agents for use in such imaging. More specifically, the present invention concerns novel azidoalkyl derivatives of targeting molecules, i.e. molecules having an affinity to a specific target such as a ligand for a receptor, which may be utilized for the preparation of "mTc labeled agents which serve for radioimaging.
The present invention further concerns the preparation of these azidoalkyl derivatives, radiolabelled agents prepared therefrom and the preparation of these agents and kits containing said derivatives.
LIST OF REFERENCES
1. Scatton B. et al, Neurology 32, 1039 (1982). 2. Lee T. et al. Nature, 273, 59 (1978)
3. Reisine T.D, et al. Life Sci. 21, 1123 (1977).
4. Goetz C.G. et al., Clin. Neuropharmacol. 5, 3 (1982)
5. Lee T. and Seeman P.S., "In Receptors for Neuro-transmitters and Peptide Hormones" (Eds. Pepeu G. Kuhar M.J. and Enna S.J.) p. 435 New York, Raven Press 1980.
6. Wagner H.N. Jr. et al., Science 221, 1264 (1983).
7. Wong D.F. et al. Science, 234, 1558 (1986).
8. Maziere B. et al. Life Sci. 35, 1349 (1984).
9. Arnett CD. et al. J. Nucl. Med. 27, 1878 (1987).
10. Arnett CD. et al. Life Sci. 36, 1359 (1985). 11. Satyamurthy N. et al, Nucl. Med. Biol. 13, 617 (1986).
12. Welch M.J. et al, Nucl. Med. Biol. 15, 83 (1986) and references cited therein.
13. Cholon S. et al, Nucl. Med. Biol.17, 389 (1990).
14. Ballinger J.R. et al, Appl. Radiat. Isot. 40, 547 (1988). 15. Baldas J, Int. J. Appl. Radiat. Isot. 26, 133 (1985).
16. Pusqualini, R, et al, Appl. Radiat. Isot. 43, 1329 (1992).
17. Janssen Pharmaceutica, Analytical Report (1990).
18. Kiesewetter D.O. et al, Appl. Rad. Isot. 37, 1181 (1986).
19. Hassner A. and Stern M, Angew. Chem. lnt, Ed. Engl. 25, 478 (1986).
20. Hassner A. et al, J. Org. Chem, 55, 2304 (1989).
The above references will be referred to in the following text by indicating in brackets their relevant number in the above list.
BACKGROUND OF THE INVENTION AND PRIOR ART
Imaging is a tool of major importance in medical diagnosis, evaluation of treatment efficacy and in basic medical research. Recently the advent of functional imaging techniques such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) turned functional brain imaging into a field of increasing importance in the area of medical imaging.
The in vivo imaging of D2-dopamine receptors (to be referred to at times as "D2 receptors") is very important for basic research, diagnosis
and therapy of various neurological and psychiatric disorders such as Parkinson's disease (Scatton et al. 1982; Lee et al. 1980), Huntington's chorea (Reisine et al, 1977), tardive dyskinesia (Goetz et al, 1982) and schizophrenia (Lee et al, 1980). Spiperone, a neuroleptic molecule which has a high affinity for D2 receptors has been used for D, receptors imaging mostly by the PET technique. The spiperone derivatives prepared for use in PET imaging have been labeled with nC (Wagner et al, 1983; Wong et al, 1986), 76Br (Maziere et al, 1984) and 18F (Arnett et al, 1987; Arnett et al, 1985; Satyamurthy et al, 1986; Welch et al, 1986) with the 18F being the most useful due to its relatively longer half-life and its relative ease of production and superior emission characteristics. However the relative short half-life of these radioisotopes, their high prices and the very high costs involved in the establishment of a PET center greatly reduces the wide¬ spread use of D2 receptors imaging by this technique. In view of the fact that SPECT type imaging is a more accessible technology in that the equipment is less costly and in that the radioactive substances therefore are more easily manufactured, considerable efforts have been invested in developing suitable γ -emitting agents in general and such which are specific for D2-receptor imaging in particular. Spiperone labeled with 125I has recently been prepared and animal studies have shown its specific uptake by the striatum which contains the most dense population of D2 receptors (Cholon et al, 1990). However, 125I labeling has a number of disadvantages which considerably limit its use, for one it is known that iodine-labeled materials are often unstable under physiological conditions; additionally, 125I has a short half-life; and furthermore the preparation of radioactive iodine is relatively expensive.
"Tc is the most widely used radioisotope in today's nuclear medicine. This is due to the fact that the energy of its γ-irradiation is suitable for medical purposes, it is readily available and it has a low price.
In most cases, the approach to 99mTc complexation has generally been to bind "" c to a known chelate and thereafter modify the chelate to enable its binding to the molecule responsible for localization in the body. This approach invariably causes large changes in the physical and biological characteristics of the 99mTc labeled molecule.
It was found several years ago that azide anion may form inorganic complexes with 99mTc (Baldas, 1985).
A "mTc spiperone complex which has been prepared recently and which structure has not been determined in detail was found to be only moderately stable in aqueous solutions and to have a very low brain uptake (Ballinger et al, 1988).
In spite of the long-felt need for an efficient and inexpensive agent for use in functional imaging of D2 receptors and the like, no such agents are available to date.
OBJECTS OF THE INVENTION
It is therefore the object of the present invention to provide novel compounds useful for the preparation of "mTc labeled agents which may be used for functional and diagnostic radioimaging. It is a further object of the present invention to provide a kit which may be used by a diagnostic laboratory for the preparation of 99mTc labeled agents for use in radioimaging.
It is a still further object, according to said preferred embodiment to provide such a kit which may be used for the preparation of 99mTc labelled agents for use in D2 receptors radioimaging.
SUMMARY OF THE INVENTION
The invention is based on a new approach of direct labeling of a targeting molecule with 99mTc. In accordance with the invention novel compounds useful for the preparation of 99mTc complexes which may be utilised in radioimaging are provided.
The complexes prepared according to the present invention do not use bulky chelates to bind the 99mTc to the targeting molecules and accordingly there are only minimal changes in the structural and binding characteristics of said targeting molecule.
The present invention thus provides a compound of the formula I:
T -R -Y
wherein
T is a targeting group derived from a molecule T which has an affinity to a specific body tissue said targeting group essentially retaining the specific affinity of said molecule; R is a branched or straight alkane chain having 1 to 6 carbon atoms; and Y is azide (-N3).
T may be derived from a large number of T molecules each one having an affinity to a specific tissue. Such molecules may be ligands of receptors, various agents which have an affinity to certain types of cells or tissue, agents which avoid certain cells or tissue and the like. Examples of such T molecules are the following: (i) Ligands of dopamine receptors such as azidoalkylspiperone derivatives, represented by the following formula II
or various benzamides having the following formula III
(ii) specific ligands of brain and heart muscarinic receptors such as quinalidinyl benzylate (QNB) derivatives of the general formula IV
(iii) synthetic ionophorcs which may be utilized in brain imaging such as those having the general formula V
R,
\
C - [ CH2O (CH2)n CONHCHR (CH2)m CO (NOHR;) ]2 V
R /
In the above formulae II-V, groups Ra to R. independently represent the group RH, wherein R is as defined for formula I, and m and n are integers which are independently 0-6. R in the above Formulae I-V has preferably 1 to 4 carbon atoms, with 2 carbon atoms being the most preferred.
In accordance with a preferred embodiment T is spiperone, which is a ligand of the D2 receptor and which is represented by the following formula VI
The present invention also provides a process for preparing a compound of the formula I comprising the steps:
(a) providing a T' molecule, in a reactive form if required;
(b) reacting the molecule of step (a) with a di-p-tosylate having the general formula VII
wherein R is as defined above for formula I; and
(c) reacting the product of step (b) with a compound capable of donating an azide anion, e.g. amberlite azide. The reaction product of step (c) in the above process may suitably be separated from the reaction mixture by chromatography. In accordance with the present invention, there is also provided a method for the preparation of a radioisotopic agent useful for in vivo imaging comprising:
(a) preparing an aqueous solution of the compound of formula I;
(b) preparing a reaction mixture by adding an acid and a solution of pertechnetate of 99mTc (a salt solution of 99mTcO4 ~); ,
(c) providing appropriate reaction conditions whereby a complex of 99mTc with the compound of formula I is formed.
It is known (Pasqualini et al, 1992) that phosphines or diphospines, particularly such with the general formula: P(R5)3 or
wherein
R5 is independently in each case alkyl, aryl, arylalkyl, heteroaryl, and hεteroarylalkyl, optionally substituted by a functional group such as SO3, CN, OH, SH and NH3; X is CH,; and n is 1, 2 or 3;
can be used as oxygen acceptors in organometallic reactions such as the one described above with TcO4 ". Using such an oxygen acceptor is expected to increase the yield of the final spiperone-99mTc complex and accordingly it is preferred in accordance with the invention to add such an an oxygen acceptor to the reaction mixture in step (b) above.
The solution obtained in method step (c) may be used for imaging as is or alternatively and preferably, the obtained complex is separated from the solution prior to its use. In some specific cases it might be necessary to add a base to neutralise the resulting hydronium salt of said target molecule in the complex prior to its use.
In the case of azidoethylspiperone (represented hereinbelow in short as sp-(CH2)2N3) the direct covalent binding of WmTc to the azide moiety of azidoethylspiperone may be carried out according to the following reaction scheme:
SP-(CH,)2-N3 + HAXB + TcO" 4 100°C SP-(CH2)2-N = Tc(X), wherein (i) X is an inorganic anion, such as I", Br~, Cl"; A = 1; B = 1; and C =
4; or
(ii) X is an organic anion of the structure R^OO" wherein R1 is hydrogen or a - branched or straight chain alky] optionally substituted' by halogen atoms, e.g. 1 to 3, or by hydroxyl, e.g. 1 to 3, or an organic anion of the structure R2(COOO~)2 wherein R2 is a -C6 branched or straight chain alkylene optionally substituted by halogen atoms, e.g. 1 to 3, or hydroxyl, e.g. 1 to 3. If X is a monocarboxylic acid anion c = 4, a = 1 and b = 1. If X is a dicarboxylic acid anion c = 2, a = 2 and b = 1.
In principle, any acid capable of reducing the technetium from the heptavalent state to the lower valency needed for preparing the complex may be used in accordance with the present invention. The acids may be
inorganic or organic acid, hydrochloric acid and succinic acid being presently preferred.
Examples of specific pertechnetates of 99mTc that can be used in accordance with the above method of the present invention are Na99mTc04, NH4 99mTcO4 or K"mTcO4.
Because 99mTc has a half life time of about 6 hrs it is preferred that the actual preparation of the complex be carried out only shortly before the intended use of the agent.
The present invention further provides an agent useful for radioimaging being a complexation product of the compounds of formula I and of "" c.
The invention further provides a kit which may be utilized by a diagnostic laboratory for the preparation of the above complexation product comprising at least one container holding a compound of formula I optionally containing one or more additional containers holding a suitable acid solution.
EXAMPLES:
The present invention will now be illustrated with reference to azidoethylspiperone and its synthesis. It is understood that the invention is not limited thereto.
Spiperone
Spiperone hydrochloride (500 mg) was dissolved by heating in distilled water (105 ml). After cooling IN NaOH (1.23 ml) was added. The solution was filtered and then dried under high vacuum resulting in 376 mg of spiperone (82% yield). The product was identified by TLC, m.p. and microanalysis. The m.p. was found to be 208-210°C (lit m.p. 208.6- 210°C (Janssen Pharmaceutica, 1990)). Micronalysis:
P-tosylatoethylspiperone
To a solution of spiperone (342 mg) in hot benzene (40 ml) tetrabutyl ammonium hydrogen sulfate (78 mg) and 50% w/v NaOH (1.22 ml) were added. After 10 minutes reflux ethylene glycol di-p-tosylate in benzene (718 mg/10 ml) was added in one portion. The solution was refluxed vigorously with stirring during 20 min. Water was then added and the reaction mixture was extracted four times with methylene chloride.
Flash chromatographic separation of the crude product (with methylene chloride -methanol 95:5) afforded 340 mg (60% yield) of the desired product as a light foam. The product (p-tosylatoethylspiperone)
Azidoethylspiperone
P-tosylatoethylspiperone (261 mg) was dissolved in acetonitrile (20.5 ml) and amberlite azide (10.2 gr), prepared according to Hassner (Hassner et al, 1986; Hassner et al, 1989) was added to the solution. The slurry was shaken in a water bath at 50°C overnight.
Filtration and evaporation afforded 175 mg crude product which was purified by flash chromatography (methylene chloride - methanol 95:5). 120 mg of the oily product (56% yield) were obtained.
Azidoethylspiperone having the formula
Spectrometric analysis:
NMR data of spiperone azide: Η NMR (CDC13)(<5): 7.15(2H)(JHF=9HZ); 8.04(2H)(JHF=5.5HZ); 3.04(2H);
2.01(2H); 2.56(2H); 2.87(4H); 1.72(2H); 2.63(2H); 4.77(2H); 3.59(4H);
6.94(2H); 7.28(2H); 6.91(1H).
Η NMR(C6D6)( 5): 6.69(2H)(JHF=8.5Hz); 7.70(2H)(JHF=5.5Hz); 2.54(2H);
1.88(2H); 2.33(2H); 3.05(2H); 2.70(2H); 1.58(2H); 2.70(2H); 4.15(2H); 2.71(2H); 2.90(2H); 6.83(2H); 7.18(2H); 6.83(1H).
133.7; 198.5; 36.9; 21.9; 57.5; 49.5; 29.4; 60.7; 174.8; 64.6; 40.9; 49.5;
142.9; 116.5; 129.2; 119.7.
Mass spectrum of azidoethylspiperone: 465.3(100%)(M++1); 437.2(45 %)(M+-28;M+-N2); 396.1(5%)(M+-69;M+- H3N3); 339.1(6%)(M+-126; (M+-C4H6N4O).
Complexation of azidoethylspiperone with 99,nTcO4 "
The direct covalent binding of 99mTc to the azidoethyl moiety of the azidoethylspiperone was carried out as follows:
Azidoethylspiperone (2 mg) was dissolved in saline (1 ml) by heating and stirring for 15 min at 100°C. 2.6 ml 10 N HCl were added while continuing heating during 4 min. 1 ml saline solution of "mTcO "was added and the reaction mixture was heated further during 30 min.
After cooling, the reaction mixture was separated by one and two dimensional chromatography on silica TLC plates. One dimensional TLC was performed in acetonitrile. Two dimensional chromatography was performed in MeOH-Benzene-CH2Cl2- DDW (2:1:1:0.05). The plates were cut into strips and counted. The labeled spiperone complex had a yield of 30-50%.
Complexation of rhenium with azidoethylphenyl
Rhenium (Re) is a compound of group Vllb of the periodic table of chemical elements, to which group technetium also belongs, and accordingly the chemical properties of these two compounds are very similar. The preparation of a complex with Re is thus very similar to the preparation of a complex with "mTc.
34 mg of phenylethylazide having the following formula:
was dissolved in 42 ml ethanol and heated to 70°C for 15 min. Then 110 ml of a 10 N solution of HCl was added and the resulting solution was maintained at the same temperature for an additional 4 min. 52.9 mg of KReO4 in 42 ml saline were then added and the reaction mixture was maintained at 70°C for one and a half hours.
The reaction was then neutralized with sodium bicarbonate at pH7. The complex having the suggested formula
was then extracted with CH,C12 (4 repeats) and washed with saline at pH7. The extraction product was separated on preparative silica T.L.C. plates using CH2C12 as the eluting solvent. Fraction 3 (R)=0.4) was isolated and identified by mass spectroscopy as having the mass corresponding to the above Re complex.
Claims
1. A compound of the formula I:
T -R -Y I
wherein
T is a targeting group derived from a molecule T which has an affinity to a specific body tissue said targeting group essentially retaining the specific affinity of said molecule;
R is a branched or straight alkane chain having 1 to 6 carbon atoms; and
Y is azide -N3
2. A compound according to Claim 1, wherein T is a targeting group derived from a molecule selected from the group consisting of ligands of receptors, various agents which have an affinity to certain types of cells or tissue and agents which avoid certain cells and tissue.
3. A compound according to Claim 1 wherein T is derived from a molecule selected from ligands of dopamine receptors, ligands of muscarinic receptors, markers of hypoxic and ischemic cells and synthetic ionophores.
4. A compound according to Claim 1 being a spiperone derivative and represented by the formula VI
5. A compound according to Claim 1, wherein R is a branched or straight alkane chain having 1 to 4 carbon atoms.
6. A compound according to Claim 5, wherein R has two carbon atoms.
7. A compound according to Claim 6 being azidoethylspiperone.
8. A process for preparing a compound of the formula I comprising the steps:
(a) providing a T molecule, in a reactive form if required;
(b) reacting the molecule of step (a) with an di-p-tosylate derivative having the general formula VII
(c) reacting the product of step (b) with a compound capable of donating an azide anion.
9. A method for the preparation of a radioisotopic agent useful for in vivo imaging comprising:
(a) preparing an aqueous solution of the compound of formula I;
(b) preparing a reaction mixture by adding an acid and a solution of pertechnetate of 99mTc (a salt solution of °9mTcO4-);
(c) providing appropriate reaction conditions whereby a complex of 99mTc with the compound of formula I is formed.
10. A method according to Claim 9 comprising adding a phosphine or a diphosphine to said reaction mixture.
11. A method according to Claim 9, wherein said acid is HCl.
12. A method according to Claim 9, wherein said pertechnetate is selected from the group consisting of Na99mTcO4, NH4 99mTcO4 or K99mTcO4
13. A complexation product of the compound of formula I in Claim 1 and 99mTc.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU75252/94A AU7525294A (en) | 1993-08-13 | 1994-08-12 | Azide derivatives suitable for preparation of 99mtc complexes for imaging and their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL106,692 | 1993-08-13 | ||
IL106692A IL106692A (en) | 1993-08-13 | 1993-08-13 | AZIDOALKYL DERIVATIVES AND THEIR USE FOR THE PREPARATION OF 99mTc COMPLEXES FOR IMAGING |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995005388A1 true WO1995005388A1 (en) | 1995-02-23 |
Family
ID=11065160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/009107 WO1995005388A1 (en) | 1993-08-13 | 1994-08-12 | AZIDE DERIVATIVES SUITABLE FOR PREPARATION OF 99mTc COMPLEXES FOR IMAGING AND THEIR USE |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7525294A (en) |
IL (1) | IL106692A (en) |
WO (1) | WO1995005388A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006038184A2 (en) * | 2004-10-07 | 2006-04-13 | Koninklijke Philips Electronics N.V. | Compounds, kits and methods for use in medical imaging |
WO2007039858A2 (en) * | 2005-10-04 | 2007-04-12 | Koninklijke Philips Electronics N.V. | Targeted imaging and/or therapy using the [3+2] azide-alkyne cycloaddition |
JP2010523687A (en) * | 2007-04-09 | 2010-07-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 1,3,8-Trisubstituted-1,3,8-triaza-spiro [4.5] decan-4-one derivatives as ORL-1 receptor ligands for the treatment of anxiety and depression |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3293242A (en) * | 1961-07-21 | 1966-12-20 | Beecham Group Ltd | Alpha-azidobenzyl penicillins |
US4739060A (en) * | 1985-08-26 | 1988-04-19 | Sumitomo Chemical Company, Limited | Radioactive and non-radioactive iodobutyrophenone derivative |
US4871527A (en) * | 1987-04-29 | 1989-10-03 | The United States Of America As Represented By The United States Department Of Energy | No-carrier-added [18 F]-N-fluoroalkylspiroperidols |
US4943523A (en) * | 1984-01-30 | 1990-07-24 | Enzo Biochem, Inc. | Detectable molecules, method of preparation and use |
US4945162A (en) * | 1986-12-26 | 1990-07-31 | Sumitomo Chemical Company, Limited | Novel radioactive propyl 2-iodospiroperidol and processes for the preparation thereof |
US4971959A (en) * | 1987-04-14 | 1990-11-20 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
US5124471A (en) * | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
US5159090A (en) * | 1989-07-07 | 1992-10-27 | Eli Lilly And Company | Enantioselective synthesis of antifolates |
-
1993
- 1993-08-13 IL IL106692A patent/IL106692A/en not_active IP Right Cessation
-
1994
- 1994-08-12 AU AU75252/94A patent/AU7525294A/en not_active Abandoned
- 1994-08-12 WO PCT/US1994/009107 patent/WO1995005388A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3293242A (en) * | 1961-07-21 | 1966-12-20 | Beecham Group Ltd | Alpha-azidobenzyl penicillins |
US4943523A (en) * | 1984-01-30 | 1990-07-24 | Enzo Biochem, Inc. | Detectable molecules, method of preparation and use |
US4739060A (en) * | 1985-08-26 | 1988-04-19 | Sumitomo Chemical Company, Limited | Radioactive and non-radioactive iodobutyrophenone derivative |
US4945162A (en) * | 1986-12-26 | 1990-07-31 | Sumitomo Chemical Company, Limited | Novel radioactive propyl 2-iodospiroperidol and processes for the preparation thereof |
US4971959A (en) * | 1987-04-14 | 1990-11-20 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
US4871527A (en) * | 1987-04-29 | 1989-10-03 | The United States Of America As Represented By The United States Department Of Energy | No-carrier-added [18 F]-N-fluoroalkylspiroperidols |
US5159090A (en) * | 1989-07-07 | 1992-10-27 | Eli Lilly And Company | Enantioselective synthesis of antifolates |
US5124471A (en) * | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
Non-Patent Citations (4)
Title |
---|
APPL. RADIAT. ISOT., Vol. 40(6), 1989, BALLINGER et al., "Technetium-99m Radiopharmaceutical for Dopamine Receptor Imaging With SPECT", pages 547-549; & CHEMICAL ABSTRACTS, 111:129892. * |
INORG. CHIM. ACTA., Vol. 141(2), 1988, BALDAS et al., "The Preparation, Characterization and Reactions...", pages 153-154; & CHEMICAL ABSTRACTS, 108:197162. * |
INORG. CHIM. ACTA., Vol. 176(1), 1990, ABRAM et al., "Detection of Nitridotechnetate (VI) Complexes With Coordinated Azidoligands...", pages 139-142; & CHEMICAL ABSTRACTS, 114:74158. * |
INORG. CHIM. ACTA., Vol. 179(2), 1991, BALDAS et al., "Preparation of the Technetium (VI) Aqua Nitrido Complexes...", pages 189-194; & CHEMICAL ABSTRACTS, 115:20904. * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006038184A2 (en) * | 2004-10-07 | 2006-04-13 | Koninklijke Philips Electronics N.V. | Compounds, kits and methods for use in medical imaging |
WO2006038184A3 (en) * | 2004-10-07 | 2006-06-22 | Koninkl Philips Electronics Nv | Compounds, kits and methods for use in medical imaging |
WO2007039858A2 (en) * | 2005-10-04 | 2007-04-12 | Koninklijke Philips Electronics N.V. | Targeted imaging and/or therapy using the [3+2] azide-alkyne cycloaddition |
WO2007039858A3 (en) * | 2005-10-04 | 2009-02-19 | Koninkl Philips Electronics Nv | Targeted imaging and/or therapy using the [3+2] azide-alkyne cycloaddition |
JP2010523687A (en) * | 2007-04-09 | 2010-07-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 1,3,8-Trisubstituted-1,3,8-triaza-spiro [4.5] decan-4-one derivatives as ORL-1 receptor ligands for the treatment of anxiety and depression |
Also Published As
Publication number | Publication date |
---|---|
AU7525294A (en) | 1995-03-14 |
IL106692A0 (en) | 1993-12-08 |
IL106692A (en) | 1997-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5387409A (en) | Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group | |
Gona et al. | [18 F] Fluorination of o-carborane via nucleophilic substitution: towards a versatile platform for the preparation of 18 F-labelled BNCT drug candidates | |
EP0337654B1 (en) | Ligands and cationic complexes thereof with technetium-99m | |
Henriksen et al. | Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F] fluorocholine ([18F] dOC) | |
Zhang et al. | Synthesis and biological evaluation of a novel 99mTc nitrido radiopharmaceutical with deoxyglucose dithiocarbamate, showing tumor uptake | |
Li et al. | Synthesis and biodistribution of novel 99m Tc labeled 4-nitroimidazole dithiocarbamate complexes as potential agents to target tumor hypoxia | |
EP1021205B1 (en) | Synthesis of ferrocenyl phenyltropane analogs and their radio-transformation to technetium neuroprobes for mapping monoamine reuptake sites | |
WO1995005388A1 (en) | AZIDE DERIVATIVES SUITABLE FOR PREPARATION OF 99mTc COMPLEXES FOR IMAGING AND THEIR USE | |
EP0713513B1 (en) | Tris(isonitrile)copper(i) sulfates for preparing radionuclide complexes | |
JPS58502203A (en) | r-releasing receptor-binding 3-quinuclidinyl glycolate, its production method, and image forming method and assay method using the same | |
Maresca et al. | Synthesis, characterization, and biodistribution of a Technetium-99m ‘3+ 1’fatty acid derivative. The crystal and molecular structures of a series of oxorhenium model complexes | |
US5919797A (en) | Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites | |
Sogbein et al. | Aqueous fluoride and the preparation of [99mTc (CO) 3 (OH2) 3]+ and 99mTc− carborane complexes | |
EP0395695A4 (en) | Tris(isonitrile)copper(i) adducts for preparing radionuclide complexes | |
Katti et al. | A new neutral-lipophilic 99mTc complex with a bis-hydrazide-phosphine (BHP) ligand | |
EP2708547B1 (en) | Aqueous solutions of radiometal complexes with tridentate ligends | |
EP2032590A1 (en) | Triazole containing metal chelating agents | |
Yang et al. | Synthesis of several MPP derivatives for 99m Tc-labelling and evaluated as potential 5-HT 1A receptor imaging agents | |
US5602236A (en) | Metal-containing steroid mimics and ligands useful in the preparation thereof | |
Gagnon et al. | Radiotracers based on technetium-94m | |
US20060062725A1 (en) | Methods for preparing metal-carborane complexes for radioimaging and radiotherapy | |
Zhang et al. | Preparation, quality control and physico-chemical properties of 99m Tc-BAT-AV-45 | |
EP2099452B1 (en) | Tricarbonyl complexes with tridentate chelators for myocardium imaging | |
Moura et al. | 99mTc (I) scorpionate complexes for brain imaging: Synthesis, characterization and biological evaluation | |
Jalilian et al. | Synthesis, radiolabeling and stability of new nitrophenol complexes of Technetium-99m as possible hypoxia imaging radiopharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |